Emerging treatments for chronic hepatitis C

Journal of the Formosan Medical Association

Volumn 114, Issue 3, 2015, Pages 204-215

  Hayes, C Nelson ^a,b   Chayama, Kazuaki ^a,b,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Clinical trials; Direct acting antiviral; Interferon free therapy; NS3 4A protease inhibitor; NS5A inhibitor; NS5B RNA dependent RNA polymerase

Indexed keywords

ABT 072; ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DANOPREVIR; DASABUVIR; DELDEPREVIR; DELEOBUVIR; FALDAPREVIR; FILIBUVIR; GRAZOPREVIR; IDX 320; INTERFERON; LOMIBUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RADALBUVIR; RIBAVIRIN; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VEDROPREVIR; ALPHA INTERFERON; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ALERTNESS; AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL RESISTANCE; ARTHRALGIA; BINDING SITE; CHRONIC HEPATITIS C; CLINICAL RESEARCH; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSGEUSIA; FATIGUE; FEVER; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; JAUNDICE; LIFESTYLE MODIFICATION; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRURITUS; RASH; REVIEW; SKIN DEFECT; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; PROLINE;

EID: 84930379996     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2014.09.001     Document Type: Review

References (71)

1. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(Suppl. 1):74-81.
3. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
4. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
5. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
6. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
7. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
8. Schinazi R., Halfon P., Marcellin P., Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014, 34(Suppl. 1):69-78.
9. Yang W.L., Lee J.Y. Extensive inflammation of actinic keratoses during interferon alpha therapy for chronic hepatitis C in a Taiwanese albino woman. J Formos Med Assoc 2013, 112:728-729.
10. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996, 25:283-291.
11. Perni R.B., Almquist S.J., Byrn R.A., Chandorkar G., Chaturvedi P.R., Courtney L.F., et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrobial Agents and Chemotherapy 2006, 50:899-909.
12. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
13. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van Vliet A., van de Wetering de Rooij J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131:997-1002.
14. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Müh U., Welker M., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
15. Chou R., Hartung D., Rahman B., Wasson N., Cottrell E.B., Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013, 158:114-123.
16. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
17. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
18. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
19. Sherman K.E., Flamm S.L., Afdhal N.H., Nelson D.R., Sulkowski M.S., Everson G.T., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med Sep 15 2011, 365:1014-1024.
20. Liu J., Jadhav P.R., Amur S., Fleischer R., Hammerstrom T., Lewis L., et al. Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naive and experienced subjects. Hepatology 2012, 57:897-902.
21. Kumada H., Toyota J., Okanoue T., Chayama K., Tsubouchi H., Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012, 56:78-84.
22. Hayashi N., Okanoue T., Tsubouchi H., Toyota J., Chayama K., Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012, 19:e134-e142.
23. Chayama K., Hayes C.N., Yoshioka K., Moriwaki H., Okanoue T., Sakisaka S., et al. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. Hepatol Res 2010, 40:1155-1167.
24. Butt A.A., Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012, 54:96-104.
25. Hézode C., Fontaine H., Dorival C., Zoulim F., Larrey D., Canva V., et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014, 147. 132-142.e134.
26. Hiraga N., Imamura M., Abe H., Hayes C.N., Kono T., Onishi M., et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone invivo. Hepatology 2011, 54:781-788.
27. Ozeki I., Akaike J., Karino Y., Arakawa T., Kuwata Y., Ohmura T., et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011, 46:929-937.
28. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011, 55:192-206.
29. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366:216-224.
30. Wyles D.L. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 2012, 20:139-145.
31. Wendt A., Adhoute X., Castellani P., Oules V., Ansaldi C., Benali S., et al. Chronic hepatitis C: future treatment. Clin Pharmacol 2014, 6:1-17.
32. Rosenquist Å., Samuelsson B., Johansson P.O., Cummings M.D., Lenz O., Raboisson P., et al. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem 2014, 57:1673-1693.
33. Jacobson I.M., Dore G.J., Foster G.R., Fried M.W., Radu M., Rafalsky V.V., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014, 384:403-413.
34. Manns M., Marcellin P., Poordad F., de Araujo E.S., Buti M., Horsmans Y., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014, 384:414-426.
35. Forns X., Lawitz E., Zeuzem S., Gane E., Bronowicki J.P., Andreone P., et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014, 146:1669-1679.
36. Hayashi N., Izumi N., Kumada H., Okanoue T., Tsubouchi H., Yatsuhashi H., et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014, 61:219-227.
37. Izumi N., Hayashi N., Kumada H., Okanoue T., Tsubouchi H., Yatsuhashi H., et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014, 49:941-953.
38. Zeuzem S., Berg T., Gane E., Ferenci P., Foster G.R., Fried M.W., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014, 146. 430-441.e436.
39. Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F., Weber P.C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999, 6:937-943.
40. Gerber L., Welzel T.M., Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int 2013, 33(Suppl. 1):85-92.
41. Lawitz E., Lalezari J.P., Hassanein T., Kowdley K.V., Poordad F.F., Sheikh A.M., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013, 13:401-408.
42. Kowdlev K.V., Läwitz E., Crespo I., Hassanein T., Davis M., DeMicco M., et al. 1 ATOMIC: 97% RVR for PIS7977 + REG/RBV × 12 week regimen in HCV GT1: end to response-guided therapy?. J Hepatol. 2012, 56(Suppl. 2):S1.
43. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
44. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5:453-463.
45. Lee C. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy. Arch Pharm Res 2011, 34:1403-1407.
46. Quezada E.M., Kane C.M. The hepatitis C virus NS5A stimulates NS5B during invitro RNA synthesis in a template specific manner. Open Biochem J 2009, 3:39-48.
47. Pawlotsky J.M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013, 59:375-382.
48. Ascher D.B., Wielens J., Nero T.L., Doughty L., Morton C.J., Parker M.W. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep 2014, 4:4765.
49. Chayama K., Takahashi S., Toyota J., Karino Y., Ikeda K., Ishikawa H., et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55:742-748.
50. Lok A.S., Gardiner D.F., Hézode C., Lawitz E.J., Bourlière M., Everson G.T., et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014, 60:490-499.
51. Kumada H., Suzuki Y., Ikeda K., Toyota J., Karino Y., Chayama K., et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014, 59:2083-2089.
52. Manns M., Pol S., Jacobson I.M., Marcellin P., Gordon S.C., Peng C.Y., et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014, 384:1597-1605.
53. Everson G.T., Sims K.D., Rodriguez-Torres M., Hézode C., Lawitz E., Bourlière M., et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014, 146:420-429.
54. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221.
55. Afdhal N., Reddy K.R., Nelson D.R., Lawitz E., Gordon S.C., Schiff E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
56. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
57. Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014, 370:1879-1888.
58. Jacobson I.M., Gordon S.C., Kowdley K.V., Yoshida E.M., Rodriguez-Torres M., Sulkowski M.S., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-1877.
59. Zeuzem S., Dusheiko G.M., Salupere R., Mangia A., Flisiak R., Hyland R.H., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014, 370:1993-2001.
60. Lawitz E., Sulkowski M.S., Ghalib R., Rodriguez-Torres M., Younossi Z.M., Corregidor A., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
61. Poordad F., Lawitz E., Kowdley K.V., Cohen D.E., Podsadecki T., Siggelkow S., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013, 368:45-53.
62. Feld J.J., Kowdley K.V., Coakley E., Sigal S., Nelson D.R., Crawford D., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1594-1603.
63. Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Cooper C., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370:1983-1992.
64. Zeuzem S., Jacobson I.M., Baykal T., Marinho R.T., Poordad F., Bourlière M., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1604-1614.
65. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuzem S., Agarwal K., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
66. Zeuzem S., Soriano V., Asselah T., Bronowicki J.P., Lohse A.W., Müllhaupt B., et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013, 369:630-639.
67. Lawitz E., Poordad F., Kowdley K.V., Cohen D.E., Podsadecki T., Siggelkow S., et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013, 59:18-23.
68. Gane E.J., Pockros P.J., Zeuzem S., Marcellin P., Shikhman A., Bernaards C., et al. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int 2014, 10.1111/liv.12588.
69. Hezode C., Serfaty L., Vierling J., Kugelmas M., Pearlman B., Sievert W., et al. Safety and efficacy of the all-oral regimen of MK-5172/MK-8742±ribavirin in treatment-naive, non-cirrhotic, patients with hepatitis C virus genotype 1 infection: the C-WORTHy study. 49th Annual Meeting of the European Association for the Study of the Liver 2014, vol. 60:S55. Elsevier, London, United Kingdom.
70. Lawitz E., Hezode C., Gane E., Tam E., Lagging M., Balart L., et al. Efficacy and safety of MK-5172 and MK-8742±ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-WORTHy study. 49th Annual Meeting of the European Association for the Study of the Liver 2014, vol. 60:S25. Elsevier, London, United Kingdom.
71. Soriano V., Vispo E., de Mendoza C., Labarga P., Fernandez-Montero J.V., Poveda E., et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013, 14:1161-1170.